Relationship Between General Cognition,Visual Assessed Cortical Atrophy,and Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease: A Cross-Sectional Study from a Chinese PUMCH Cohort
Restricted accessResearch articleFirst published online June 29, 2021
Relationship Between General Cognition,Visual Assessed Cortical Atrophy,and Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease: A Cross-Sectional Study from a Chinese PUMCH Cohort
Cerebrospinal fluid (CSF) biomarkers are widely accepted as manifestations of Alzheimer’s disease (AD) pathogenesis and incorporated into biological definition of AD. However, the correlations between CSF and other biomarkers such as neuroimaging and neuropsychiatric evaluation are complicated and inconsistent.
Objective:
We aimed to better interpreting CSF biomarkers results accompanying with other indexes in improving accurate diagnosis of AD.
Methods:
112 AD patients and 30 cognitive normal controls were selected. Commercial accessible ELISA kits were introduced for measurement of CSF t-tau, p-tau181, Aβ1–42, and NfL based on standard protocol. MRI examinations were performed using a 3-T MRI scanner and visual rating scales including medial temporal atrophy score and Koedam’s scale were used to evaluate medial temporal atrophy and posterior region atrophy.
Results:
CSF biomarkers’ profile including decreased concentration of Aβ1–42, increased concentration of t-tau, p-tau181, t-tau/Aβ 1–42, and NfL were diagnostic between AD and control. CSF biomarkers profile was not influenced by the APOE genotype. Increased concentration of t-tau and NfL, as well as ratio of t-tau/Aβ 1–42 were related to decrease of Mini-Mental State Examination (MMSE) score while concentration of Aβ1–42 not. Visual assessed cortical atrophy was related to MMSE score, but most of the CSF biomarkers were not related to atrophy, except that increased concentration of p-tau181 was significantly associated with atrophy of posterior cortical region.
Conclusion:
Our results supported CSF biomarkers were helpful in diagnosis of AD. However, CSF biomarkers were cross-sectional reflection of pathogenesis, which did not correlate well with clinical progression. CSF biomarkers should be interpreted in combination with MRI and cognitive evaluation in clinical use.
OlssonB, LautnerR, AndreassonU, ÖhrfeltA, PorteliusE, BjerkeM, HölttäM, RosénC, OlssonC, StrobelG, WuE, DakinK, PetzoldM, BlennowK, ZetterbergH (2016) CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis. Lancet Neurol15, 673–684.
2.
Sheikh-BahaeiN, SajjadiSA, PierceAL (2017) Current role for biomarkers in clinical diagnosis of Alzheimer disease and frontotemporal dementia. Curr Treat Options Neurol19, 46.
JoachimLK, FrölichL, RütherE, WiltfangJ, MaierW, KornhuberJ, BauerC, HeuserI, PetersO (2018) Correlation of CSF- and MRI-biomarkers and progression of cognitive decline in an open label MCI trial. J Prev Alzheimers Dis5, 202–206.
6.
VemuriP, WisteHJ, WeigandSD, ShawLM, TrojanowskiJQ, WeinerMW, KnopmanDS, PetersenRC, JackCRJr., Alzheimer’s Disease Neuroimaging Initiative (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change. Neurology73, 294–301.
7.
MckhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr., KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease. Alzheimers Dement7, 263–269.
8.
TanJP, LiN, GaoJ, Wang ZhaoLN YM, YuBC, DuW, ZhangWJ, CuiLQ, WangQS, LiJJ, YangJS, YuJM, XiaXN, ZhouPY (2015) Optimal cutoff scores for dementia and mild cognitive impairment of the Montreal Cognitive Assessment among elderly and oldest-old Chinese population. J Alzheimers Dis43, 1403–1412.
9.
ScheltensP, LeysD, BarkhofF, HugloD, WeinsteinHC, VermerschP, KuiperM, SteinlingM, WoltersE, ValkJ (1992) Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: Diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry55, 967–972.
10.
KoedamEL, LehmannM, Van Der FlierWM, ScheltensP, PijnenburgYA, FoxN, BarkhofF, WattjesMP (2011) Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol21, 2618–2625.
11.
KhanTK, AlkonDL (2015) Alzheimer’s disease cerebrospinal fluid and neuroimaging biomarkers: Diagnostic accuracy and relationship to drug efficacy. J Alzheimers Dis46, 817–836.
12.
SeeburgerJL, HolderDJ, CombrinckM, JoachimC, LaterzaO, TanenM, DallobA, ChappellD, SnyderK, FlynnM, SimonA, ModurV, PotterWZ, WilcockG, SavageMJ, SmithAD (2015) Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer’s disease from other dementias and healthy controls in the OPTIMA Cohort. J Alzheimers Dis44, 525–539.
13.
VandersticheleH, BiblM, EngelborghsS, BastardN, LewczukP, MolinuevoJL, ParnettiL, Perret-LiaudetA, ShawLM, TeunissenC, WoultersD, BlennowK (2012) Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: A consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. Alzheimers Dement8, 65–73.
VemuriP, WisteHJ, WeigandSD, KnopmanDS, ShawLM, TrojanowskiJQ, AisenPS, WeinerM, PetersenRC, JackCRJr., Alzheimer’s Disease Neuroimaging Initiative (2010) Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol67, 308–316.
16.
GalaskoD, ChangL, MotterR, ClarkCM, KayeJ, KnopmanD, ThomasR, KholodenkoD, SchenkD, LieberburgI, MillerB, GreenR, BasheradR, KertilesL, BossMA, SeubertP (1998) High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol55, 937–945.
17.
VogelgsangJ, VukovichR, WedekindD, WiltfangJ (2019) Higher level of mismatch in APOEɛ4 carriers for amyloid-beta peptide Alzheimer’s disease biomarkers in cerebrospinal fluid. ASN Neuro11, 1759091419845524.
18.
LautnerR, InselPS, SkillbäckT, OlssonB, LandénM, FrisoniGB, HerukkaSK, HampelH, WallinA, MinthonL, HanssonO, BlennowK, MattssonN, ZetterbergH (2017) Preclinical effects of APOE ɛ4 on cerebrospinal fluid Aβ42 concentrations. Alzheimers Res Ther9, 87.
19.
Le BastardN, MartinJJ, VanmechelenE, VandersticheleH, De DeynPP, EngelborghsS (2010) Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiol Aging31, 1867–1876.
20.
LautnerR, PalmqvistS, MattssonN, AndreassonU, WallinA, PålssonE, JakobssonJ, HerukkaSK, OweniusR, OlssonB, HampelH, RujescuD, EwersM, LandénM, MinthonL, BlennowK, ZetterbergH, HanssonO, Alzheimer’s Disease Neuroimaging Initiative (2014) Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. JAMA Psychiatry71, 1183–1191.
HanssonO, ZetterbergH, BuchhaveP, LondosE, BlennowK, MinthonL (2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol5, 228–234.
23.
StefaniA, MartoranaA, BernardiniS, PanellaM, MercatiF, OrlacchioA, PieranzziM (2006) CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. J Neurol Sci251, 124–128.
24.
SunderlandT, WolozinB, GalaskoD, LevyJ, DukoffR, BahroM, LasserR, MotterR, LehtimäkiT, SeubertP (1999) Longitudinal stability of CSF tau levels in Alzheimer patients. Biol Psychiatry46, 750–755.
25.
SluimerJD, BouwmanFH, VrenkenH, BlankensteinMA, BarkhofF, Van Der FlierWM, ScheltensP (2010) Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study. Neurobiol Aging31, 758–764.
26.
JosephsKA, WhitwellJL, AhmedZ, ShiungMM, WeigandSD, KnopmanDS, BoeveBF, ParisiJE, PetersenRC, DicksonDW, JackCRJr (2008) Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol63, 204–212.
27.
DesikanRS, McevoyLK, ThompsonWK, HollandD, RoddeyJC, BlennowK, AisenPS, BrewerJB, HymanBT, DaleAM, Alzheimer’s Disease Neuroimaging Initiative (2011) Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann Neurol70, 657–661.
28.
De SouzaLC, ChupinM, LamariF, JardelC, LeclercqD, ColliotO, LehéricyS, DuboisB, SarazinM (2012) CSF tau markers are correlated with hippocampal volume in Alzheimer’s disease. Neurobiol Aging33, 1253–1257.
29.
GranadilloE, PaholpakP, MendezMF, TengE (2017) Visual ratings of medial temporal lobe atrophy correlate with CSF tau indices in clinical variants of early-onset Alzheimer disease. Dement Geriatr Cogn Disord44, 45–54.
30.
SchuffN, WoernerN, BoretaL, KornfieldT, ShawLM, TrojanowskiJQ, ThompsonPM, JackCRJr, WeinerMW, Alzheimer’s Disease Neuroimaging Initiative (2009) MRI of hippocampal volume loss in early Alzheimer’s disease in relation to APOE genotype and biomarkers. Brain132, 1067–1077.
31.
McmillanC.T., AvantsB, IrwinDJ, ToledoJB, WolkDA, Van DeerlinVM, ShawLM, TrojanoswkiJQ, GrossmanM (2013) Can MRI screen for CSF biomarkers in neurodegenerative disease?Neurology80, 132–138.
32.
StrickerNH, DodgeHH, DowlingNM, HanSD, EroshevaEA, JagustWJ, Alzheimer’s Disease Neuroimaging Initiative (2012) CSF biomarker associations with change in hippocampal volume and precuneus thickness: Implications for the Alzheimer’s pathological cascade. Brain Imaging Behav6, 599–609.
33.
FaganAM, HeadD, ShahAR, MarcusD, MintunM, MorrisJC, HoltzmanDM (2009) Decreased CSF Aβ42 correlates with brain atrophy in cognitively normal elderly. Ann Neurol65, 176–183.
34.
SchönknechtP, PantelJ, HartmannT, WerleE, VolkmannM, EssigM, AmannM, ZanabiliN, BardenheuerH, HuntA, SchröderJ (2003) Cerebrospinal fluid tau levels in Alzheimer’s disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy. Psychiatry Res120, 231–238.
35.
TosunD, SchuffN, ShawLM, TrojanowskiJQ, WeinerMW, Alzheimer’s Disease Neuroimaging Initiative (2011) Relationship between CSF biomarkers of Alzheimer’s disease and rates of regional cortical thinning in ADNI data. J Alzheimers Dis26, 77–90.
36.
SchoonenboomNS, Van Der FlierWM, BlankensteinMA, BouwmanFH, Van KampGJ, BarkhofF, ScheltensP (2008) CSF And MRI markers independently contribute to the diagnosis of Alzheimer’s disease. Neurobiol Aging29, 669–675.
37.
MöllerC, VrenkenH, JiskootL, VersteegA, BarkhofF, ScheltensP, Van Der FlierWM (2013) Different patterns of gray matter atrophy in early- and late-onset Alzheimer’s disease. Neurobiol Aging34, 2014–2022.
38.
WestmanE, MuehlboeckJS, SimmonsA (2012) Combining MRI and CSF measures for classification of Alzheimer’s disease and prediction of mild cognitive impairment conversion. Neuroimage62, 229–238.
